Citius Oncology (CTOR) Competitors $0.85 -0.12 (-12.34%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends CTOR vs. JAGX, ADXN, RDHL, VINC, SNGX, MBRX, TRAW, ENSC, OBSV, and ATHEShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Jaguar Health (JAGX), Addex Therapeutics (ADXN), RedHill Biopharma (RDHL), Vincerx Pharma (VINC), Soligenix (SNGX), Moleculin Biotech (MBRX), Traws Pharma (TRAW), Ensysce Biosciences (ENSC), ObsEva (OBSV), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical preparations" industry. Citius Oncology vs. Jaguar Health Addex Therapeutics RedHill Biopharma Vincerx Pharma Soligenix Moleculin Biotech Traws Pharma Ensysce Biosciences ObsEva Alterity Therapeutics Citius Oncology (NASDAQ:CTOR) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk. Do insiders and institutionals hold more shares of CTOR or JAGX? 70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 12.0% of Jaguar Health shares are held by institutional investors. 22.9% of Citius Oncology shares are held by insiders. Comparatively, 0.0% of Jaguar Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, CTOR or JAGX? Citius Oncology has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Which has higher valuation & earnings, CTOR or JAGX? Citius Oncology has higher earnings, but lower revenue than Jaguar Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/A$2.42MN/AN/AJaguar Health$9.76M1.26-$41.30MN/AN/A Is CTOR or JAGX more profitable? Citius Oncology has a net margin of 0.00% compared to Jaguar Health's net margin of -360.13%. Citius Oncology's return on equity of -90.25% beat Jaguar Health's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -90.25% 3.21% Jaguar Health -360.13%-326.62%-67.02% Does the MarketBeat Community prefer CTOR or JAGX? Jaguar Health received 1835 more outperform votes than Citius Oncology when rated by MarketBeat users. CompanyUnderperformOutperformCitius OncologyN/AN/AJaguar HealthOutperform Votes183588.73% Underperform Votes23311.27% Does the media favor CTOR or JAGX? In the previous week, Jaguar Health had 3 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Jaguar Health and 0 mentions for Citius Oncology. Jaguar Health's average media sentiment score of 0.71 beat Citius Oncology's score of 0.00 indicating that Jaguar Health is being referred to more favorably in the news media. Company Overall Sentiment Citius Oncology Neutral Jaguar Health Positive SummaryCitius Oncology beats Jaguar Health on 6 of the 11 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.01M$6.57B$5.23B$8.84BDividend YieldN/A8.13%5.54%4.08%P/E RatioN/A10.1393.1417.56Price / SalesN/A355.131,239.2791.27Price / Cash3.6153.8241.4336.93Price / Book-3.8710.597.236.54Net Income$2.42M$153.02M$119.93M$226.15M7 Day Performance-19.61%3.96%2.14%3.77%1 Month Performance-30.72%-6.72%-2.23%4.46%1 Year PerformanceN/A30.92%32.63%27.57% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$0.85-12.3%N/AN/A$2.01MN/A0.00N/AJAGXJaguar Health0.6683 of 5 stars$0.97-1.0%N/A-94.9%$8.96M$9.76M0.0050News CoverageADXNAddex Therapeutics2.5152 of 5 stars$8.25+11.8%$30.00+263.6%+34.5%$8.75M$1.83M-5.0330News CoverageRDHLRedHill Biopharma0.9552 of 5 stars$6.74+5.3%N/A-96.5%$8.63M$6.53M0.00210News CoverageVINCVincerx Pharma3.0874 of 5 stars$0.26-7.2%$2.00+681.3%-63.7%$8.59MN/A-0.2560SNGXSoligenix0.8266 of 5 stars$3.39-3.4%N/A-50.7%$8.51M$840,000.00-0.4520MBRXMoleculin Biotech3.0689 of 5 stars$2.78+4.1%$31.00+1,016.3%-67.0%$8.33MN/A0.0020Analyst ForecastTRAWTraws Pharma0.8598 of 5 stars$4.51+0.4%N/AN/A$8.25M$230,000.00-0.0317ENSCEnsysce Biosciences0.0385 of 5 stars$0.59-9.2%N/A-50.7%$8.22M$2.23M-0.3210Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastGap DownATHEAlterity Therapeutics2.7756 of 5 stars$1.07+1.9%$4.00+273.8%-35.5%$7.81MN/A0.0010Gap Up Related Companies and Tools Related Companies Jaguar Health Competitors Addex Therapeutics Competitors RedHill Biopharma Competitors Vincerx Pharma Competitors Soligenix Competitors Moleculin Biotech Competitors Traws Pharma Competitors Ensysce Biosciences Competitors ObsEva Competitors Alterity Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTOR) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
